Tectonic Therapeutic Files 8-K: Material Agreement & Equity Sales
Ticker: TECX · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1681087
| Field | Detail |
|---|---|
| Company | Tectonic Therapeutic, Inc. (TECX) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $50.00, $54.14, $185.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, regulation-fd
TL;DR
Tectonic Therapeutic inked a material deal and sold equity on Feb 3rd.
AI Summary
On February 3, 2025, Tectonic Therapeutic, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Tectonic Therapeutic, including a new material agreement and equity transactions, which could impact its financial position and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks, requiring further scrutiny.
Key Players & Entities
- Tectonic Therapeutic, Inc. (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- 001-38537 (company) — SEC File Number
- 81-0710585 (company) — IRS Employer Identification No.
- 490 Arsenal Way, Suite 210, Watertown, MA 02472 (company) — Business Address
FAQ
What is the nature of the material definitive agreement entered into by Tectonic Therapeutic, Inc. on February 3, 2025?
The filing states that Tectonic Therapeutic, Inc. entered into a material definitive agreement on February 3, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by Tectonic Therapeutic, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What is the primary business of Tectonic Therapeutic, Inc. according to the filing?
Tectonic Therapeutic, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
What was Tectonic Therapeutic, Inc.'s former company name and when did the name change occur?
The company was formerly known as AVROBIO, Inc. (or AvroBio, Inc.) with a name change date of January 31, 2018.
What is the filing date and the period of report for this 8-K filing?
The filing was made as of February 3, 2025, and the conformed period of report is also February 3, 2025.
Filing Stats: 1,494 words · 6 min read · ~5 pages · Grade level 13.3 · Accepted 2025-02-03 06:30:51
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TECX The Nasdaq
- $50.00 — Stock"), of the Company, at a price of $50.00 per Share to fund investors and $54.14
- $54.14 — $50.00 per Share to fund investors and $54.14 per Share to individual investors that
- $185.0 million — cement are expected to be approximately $185.0 million. The Private Placement is expected to c
Filing Documents
- d843684d8k.htm (8-K) — 34KB
- d843684dex101.htm (EX-10.1) — 177KB
- d843684dex102.htm (EX-10.2) — 123KB
- d843684dex991.htm (EX-99.1) — 10KB
- 0001193125-25-018840.txt ( ) — 553KB
- tecx-20250203.xsd (EX-101.SCH) — 3KB
- tecx-20250203_lab.xml (EX-101.LAB) — 18KB
- tecx-20250203_pre.xml (EX-101.PRE) — 11KB
- d843684d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Securities Purchase Agreement. 10.2 Form of Registration Rights Agreement. 99.1 Press release dated February 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the anticipated closing and use of proceeds of the Private Placement and the filing and timing of a resale registration statement. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to market conditions, the satisfaction of the customary closing conditions and other risks described under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, and its subsequent filings with the SEC. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TECTONIC THERAPEUTIC, INC. By: /s/ Daniel Lochner Daniel Lochner Chief Financial Officer Date: February 3, 2025